These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30367272)

  • 1. Diagnosis and Management of Neuropsychiatric Symptoms in Alzheimer's Disease.
    Wolinsky D; Drake K; Bostwick J
    Curr Psychiatry Rep; 2018 Oct; 20(12):117. PubMed ID: 30367272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotics in Alzheimer's Disease: Current Status and Therapeutic Alternatives.
    Maziero MP; Rocha NP; Teixeira AL
    Curr Alzheimer Res; 2023; 20(10):682-691. PubMed ID: 38409713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between Neuropsychiatric Improvement and Neurocognitive Change in Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Mimura M; Shigeta M
    J Alzheimers Dis; 2018; 66(1):139-148. PubMed ID: 30248052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.
    Rosenberg PB; Lanctôt KL; Herrmann N; Mintzer JE; Porsteinsson AP; Sun X; Raman R
    J Alzheimers Dis; 2016 Aug; 54(1):373-81. PubMed ID: 27567808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.
    Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K
    Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.
    Ng KP; Pascoal TA; Mathotaarachchi S; Chung CO; Benedet AL; Shin M; Kang MS; Li X; Ba M; Kandiah N; Rosa-Neto P; Gauthier S;
    Neurology; 2017 May; 88(19):1814-1821. PubMed ID: 28404803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
    Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM
    Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric Symptoms Complicating the Diagnosis of Alzheimer's Disease: A Case Report.
    Eikelboom WS; van Rooij JGJ; van den Berg E; Coesmans M; Jiskoot LC; Singleton E; Ossenkoppele R; van Swieten JC; Seelaar H; Papma JM
    J Alzheimers Dis; 2018; 66(4):1363-1369. PubMed ID: 30412494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer disease: Non-pharmacological and pharmacological management of cognition and neuropsychiatric symptoms.
    Loi SM; Eratne D; Kelso W; Velakoulis D; Looi JC
    Australas Psychiatry; 2018 Aug; 26(4):358-365. PubMed ID: 29671334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
    J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Nakajima S; Plitman E; Mihashi Y; Hayashi S; Mimura M; Nakayama K
    J Alzheimers Dis; 2016; 50(3):839-45. PubMed ID: 26836181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
    Daiello LA
    Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.